Theranos 2.0? Another Purported Tech Company Trades on Fake IP
COMMENTARY

October 22, 2019by Steven Titch
Theranos 2.0? Another Purported Tech Company Trades on Fake IP
U.S. patents granted are displayed in the hallway entrance of a manufacturing facility (ADAS).

Intellectual property policies could get a major court test this year as a real estate services company appeals a massive $706 million judgment that it stole trade secrets from a San Francisco-headquartered REtech company.

At the dispute’s onset, the jury award, handed down in, Texas court in March 2018, was a twist ending to a $5 million breach-of-contract lawsuit that Amrock, formerly known as Title Source Inc., brought against HouseCanary, a San Francisco-based developer of automated valuation model (AVM) software used in real estate. Amrock contended that HouseCanary did not deliver the promised product. HouseCanary won the case by turning the tables, claiming that Amrock tried to steal the AVM’s algorithms that the developer claims do a better job at property valuation than tools from larger competitors, such as Zillow.

In the wake of the 2018 verdict, four HouseCanary employees provided sworn affidavits that HouseCanary never possessed the technology it accused Amrock of stealing. One of the four, Anthony Roveda, who had been HouseCanary’s director of appraiser experience, further identified an Amrock executive who he said undermined his company’s case by colluding with HouseCanary CEO Jeremy Sicklick. Roveda, who left HouseCanary prior to the lawsuit, claimed, “Sicklick, in particular, was focused more on enhancing the image of the company and on fundraising than on creating a working product.”

Those disclosures mirror the more sensational case of Theranos, the never-start-up that claimed to have a machine that could do hundreds of tests on a few drops of blood collected in a tiny vial. Theranos, the creation of  Elizabeth Holmes, it turned out, had not developed anything close, and was cribbing its blood test results from larger samples using off-the-shelf technology from others.

If HouseCanary twisted the facts and claimed trade secret protections over questionable information in an attempt to push back against Amrock in hopes of netting a windfall, it worked. As of January 2017, HouseCanary had raised only $64 million in venture capital funding. Rather than defend the utility of its software, HouseCanary used trade secret protections to turn Amrock’s case into a trial over the value of its trade secrets.

The huge award—more than 10 times HouseCanary’s to-date VC funding–was based nearly exclusively on testimony from HouseCanary’s witness that the company’s trade secrets were worth $201 million. The witness offered the court no independent valuation assessments and no formula as to how that figure was calculated. Nonetheless, the jury used their subjective valuation as the basis for the award, above which were piled additional monetary and punitive damages.

Likewise, whistleblowers from HouseCanary say the company’s real estate data was generated from existing AVM software from Black Knight. Also like Theranos, HouseCanary depended heavily on one customer for validation. HouseCanary had no other customers and could produce no third-party confirmation that its products worked.

To be fair to the jury and the court, some of the details about the collusion only emerged following the trial. But if these revelations bear out, the ruling must be reversed

The sheer size of the $706 million award, one of the largest ever in an IP case, attracted questions from the legal and technology communities as well as employees of HouseCanary.

HouseCanary’s defense employed the Texas Uniform Trade Secrets Act, which includes protections of confidential business information and remedy formulas when theft occurs. While the intent may have been to offer critical protections for research and development investment, misuse can result in severe impact on competition and free markets, especially because a big award can be an infusion of capital. Much like patent abuse, it allows unscrupulous abusers to use the courts to extract profits from products that fail in the marketplace. The consequence is that the rightfully earned value of successful businesses is siphoned off into uncompetitive enterprises—resulting in significant economic and competitive costs, which will undoubtedly affect consumers.  

One lesson we have learned from Theranos is that even the savvy and vigilant can be taken in by a charismatic speaker who can hype the value of innovative technology. The story of a struggling start-up taking on entrenched corporate interests can often be compelling enough to overcome one’s healthy skepticism.   

Ultimately, HouseCanary exploited the void of skepticism and wielded its trade secret protections with surgical precision, the way detractors warn these protections often evoke troubling unintended consequences. It may fall to a higher court to decide whether the law is too vague. Until then, juries and courts should be careful about taking without question anyone’s vague or unconfirmed valuation of IP, be it a patent or trade secret, before rushing to judgment.

Steven Titch is an independent tech policy analyst focusing on cyber security, information technology, intellectual property, and telecommunications.

A+
a-
  • court ruling
  • Courts
  • intellectual property
  • lawsuit
  • patent
  • software
  • Technology
  • Theranos
  • trade secrets
  • whistleblower
  • In The News

    Health

    Voting

    Opinions

    Ensuring Equity and Innovation in Kidney Care: a Call to Action During National Kidney Month

    When you woke up this morning, you probably turned on the light, maybe looked at your phone or went to... Read More

    When you woke up this morning, you probably turned on the light, maybe looked at your phone or went to get a glass of water, all without much thought. Electricity, phone service and running water are all essentials that we give little thought to until they’re... Read More

    The American Rescue Plan Is (Still) Worth Celebrating

    Just three years ago, our economy was in the midst of an unprecedented crisis. Communities across the nation were reeling... Read More

    Just three years ago, our economy was in the midst of an unprecedented crisis. Communities across the nation were reeling not only from the health implications of the COVID pandemic, but also from high unemployment, business closures and frightening economic uncertainty. Bold and decisive action was... Read More

    Cutting Through the Generative AI Noise: What Business Leaders Should Do Now

    No matter what industry you’re in, there are two things that every business leader cares about: revenue growth and cost reduction. These are the... Read More

    No matter what industry you’re in, there are two things that every business leader cares about: revenue growth and cost reduction. These are the metrics that CEOs talk about ad nauseam during earnings calls. They are the keys that unlock higher business valuations, individual performance bonuses and the ever elusive... Read More

    Shield Our Eyes: Lawmakers Across the Country Must Ensure Eye Surgery Can Only Be Performed by Medical Eye Surgeons 

    Training and experience matter, especially when health is on the line. Just as one would rightly be concerned to discover... Read More

    Training and experience matter, especially when health is on the line. Just as one would rightly be concerned to discover a flight attendant, rather than a pilot, flying their airplane, so too would most people be alarmed to find the person performing surgery on and around... Read More

    Fentanyl Kills More Than 150 Americans Each Day, but Some States Keep Overdose Rescue Medications Out of Reach 

    Today’s growing overdose epidemic is being fueled by fentanyl, a synthetic opioid that is 50 times stronger than heroin and 100... Read More

    Today’s growing overdose epidemic is being fueled by fentanyl, a synthetic opioid that is 50 times stronger than heroin and 100 times stronger than morphine. In fact, it’s so lethal that only a tiny amount — 2 milligrams, about the size of a pencil tip — can... Read More

    Jones Act Reform Is Not a Party Issue

    Many political disagreements divide neatly along party lines, but the protectionist Jones Act isn’t one of them.  In Congress and... Read More

    Many political disagreements divide neatly along party lines, but the protectionist Jones Act isn’t one of them.  In Congress and state Capitols across America, politicians from the two major political parties can be found arguing for and against the law, which requires that all goods shipped between... Read More

    News From The Well
    scroll top